EDP-938 clinical trials
Also written EDP-938 and zelicapavir.
How each study uses EDP-938 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the EDP-938 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Moxifloxacin (1) · Tacrolimus (1) · Dabigatran (1) · Prednisone (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test EDP-938.
- Dec 2026A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusPhase 2 · Enanta Pharmaceuticals, Inc
Studies
Open first, then newest update. How each study uses EDP-938 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseaseRecruitingPhase 2/3Enanta Pharmaceuticals, IncNCT07908381Written as zelicapavir
- A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusRecruitingPhase 2Enanta Pharmaceuticals, IncNCT07482657Written as zelicapavir
- A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.CompletedPhase 2Enanta Pharmaceuticals, IncNCT05568706Written as EDP-938
- A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsCompletedPhase 1Enanta Pharmaceuticals, IncNCT06601192Written as zelicapavir (therapeutic dose)
- A Study to Evaluate EDP 938 Regimens in Children With RSVCompletedPhase 2Enanta Pharmaceuticals, IncNCT04816721Written as EDP-938
- Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractTerminatedPhase 2Enanta Pharmaceuticals, IncNCT04633187Written as EDP-938
- A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult SubjectsCompletedPhase 2Enanta Pharmaceuticals, IncNCT04196101Written as EDP-938
- A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelCompletedPhase 2Enanta Pharmaceuticals, IncNCT03691623Written as EDP-938 Dose 1
- Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT04927793Written as EDP-938
- Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT04498741Written as EDP-938
- Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT04871724Written as EDP-938
- Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03755778Written as EDP-938
- Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03750383Written as EDP-938
- A Study of EDP-938 in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03384823Written as EDP-938
What changed recently
From the registry's own updates since Oct 18, 2026.